Tocilizumab for Corticosteroid-Refractory Immune Checkpoint Inhibitor-Induced Generalized Morphea

Manon Blaise; Nathalie Cardot-Leccia; Barbara Seitz-Polski; Alexandra Picard-Gauci; Clémence Bertold; Thierry Passeron; Henri Montaudié

doi:10.1001/jamadermatol.2022.5146

Tocilizumab for Corticosteroid-Refractory Immune Checkpoint Inhibitor-Induced Generalized Morphea

JAMA Dermatol. 2023 Jan 1;159(1):112-114. doi: 10.1001/jamadermatol.2022.5146.

Authors

Manon Blaise¹, Nathalie Cardot-Leccia², Barbara Seitz-Polski³, Alexandra Picard-Gauci¹, Clémence Bertold¹, Thierry Passeron¹, Henri Montaudié¹

Affiliations

¹ Dermatology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
² Department of Pathology, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.
³ Immunology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France.

PMID: 36449277
DOI: 10.1001/jamadermatol.2022.5146

No abstract available

Plain language summary

This case report describes a 78-year old woman with a stage IIA BRAF wild-type melanoma on the left leg who experienced a grade 2 vitiligo, a marked skin thickening, and painful swelling of the limbs.

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Immune Checkpoint Inhibitors
Nivolumab
Scleroderma, Localized* / chemically induced
Scleroderma, Localized* / drug therapy

Substances

tocilizumab
Immune Checkpoint Inhibitors
Antibodies, Monoclonal, Humanized
Nivolumab